Virtual Clinical Trials Drive Success Prediction in Heart Failure Drug Development
Mayo Clinic researchers have developed virtual clinical trials using AI and real-world data to predict the success of repurposed drugs for heart failure, speeding up drug development and reducing costs.
Researchers at Mayo Clinic have pioneered an innovative approach to assess the potential effectiveness of existing drugs for treating heart failure by leveraging virtual clinical trials. This method combines sophisticated computer models with real-world patient data, streamlining the drug discovery process by reducing costs, time, and the risk of failure in traditional trials. The team developed an AI-enabled framework that emulates clinical trials by creating comparison groups from electronic health records (EHRs) of nearly 60,000 heart failure patients, allowing for the prediction of a drug's efficacy without conducting actual randomized controlled trials.
The approach incorporates drug-target modeling, which uses artificial intelligence to analyze chemical structures alongside biological data such as protein sequences and genes. This enhances the accuracy of predicting how drugs might perform in real-world settings. The researchers validated their model by retrospectively analyzing 17 drugs that had previously undergone Phase 3 trials in heart failure, successfully predicting the direction of outcomes in 7 beneficial and 10 non-beneficial cases.
This predictive capability enables scientists to identify promising repurposed drugs more efficiently, prioritizing candidates for further testing and potentially accelerating the availability of new treatments. As Dr. Nansu Zong explains, while the current model can determine whether a drug is likely to succeed, the next steps involve quantifying the level of efficacy. The technology has the potential to revolutionize clinical research by making it faster, more affordable, and more accessible, especially through a broader initiative led by Mayo Clinic under Dr. Cui Tao. This initiative explores trial emulation, simulation, and synthetic trials using AI, facilitating a new era of translational science.
Ultimately, these advancements could significantly impact how new therapies are developed and deployed, promising faster access for patients and decreased healthcare costs. Source: https://medicalxpress.com/news/2025-09-virtual-clinical-trials-success-heart.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Artificial Intelligence Enhances Detection of Breast Lesions in Mammograms
A new study reveals that AI support improves mammogram interpretation by helping radiologists detect more lesions and focusing their attention more accurately, advancing breast cancer screening techniques.
FDA Issues Safety Warnings on Boston Scientific Heart Devices Linked to Injuries and Fatalities
The FDA has issued safety warnings on Boston Scientific heart devices, alerting healthcare providers and patients about risks of device failure, injuries, and deaths associated with defibrillator wires and the Watchman stroke prevention device.
Promising Outcomes from First Prospective Study on Heart Failure in Chagas Disease Patients
A groundbreaking trial at ESC Congress 2025 reveals that sacubitril/valsartan significantly improves outcomes in patients with heart failure caused by Chagas disease, marking a milestone in managing this neglected tropical disease.
Emerging Evidence Indicates Survival Benefits of REM-Inhibition Therapy in ALS Patients
Emerging research suggests that pharmacological REM sleep inhibition may offer survival benefits for ALS patients, indicating a new direction in disease management and therapy development.